Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low